475830 — Orum Therapeutics Cashflow Statement
0.000.00%
- KR₩374bn
- KR₩284bn
- KR₩21bn
Annual cashflow statement for Orum Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | — | -63,319 | 68,217 | -5,740 |
Depreciation | ||||
Non-Cash Items | — | 22,602 | 26,100 | -701 |
Unusual Items | ||||
Purchased R&D | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | -24,645 | -1,665 | -1,845 | -7,709 |
Change in Accounts Receivable | ||||
Change in Prepaid Expenses | ||||
Change in Accounts Payable | ||||
Change in Accrued Expenses | ||||
Change in Other Liabilities | ||||
Other Operating Cash Flow | ||||
Cash from Operating Activities | -24,645 | -41,092 | 94,244 | -11,282 |
Capital Expenditures | -942 | -796 | -1,126 | -1,264 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | -30,060 | 27,498 | -1,299 | -97,197 |
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | -31,002 | 26,701 | -2,426 | -98,460 |
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 59,869 | -1,394 | 23,573 | -838 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 4,252 | -15,866 | 115,383 | -106,959 |